Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

Michael W. Jann, Troy L. ZumBrunnen, Yusuf R. Kazmi, Chad M. VanDenBerg, Hiral D. Desai, Donald J. Weidler, David A. Flockhart

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19. Methods: This was a prospective, open-label study conducted at the Clinical Research Unit School of Pharmacy. Fifty-seven healthy, nonsmoking volunteers aged 21-40 years participated. Subjects abstained from caffeinated products 12 hours prior to and during each testing period. To assess CYP2C19 activity, blood samples were collected from each subject prior to and two hours after a single dose of omeprazole 20 mg. Once PMs were identified, a sample population of EMs were selected for comparison between the two groups regarding FLV disposition. A single 100 mg FLV dose was given to EMs and PMs; blood samples for FLV analysis were obtained prior to drug administration and 0.5, 1, 2, 3, 4 6, 8, 12 and 24 hours later. A blood sample one day prior to FLV administration was also obtained for CYP2C19 and CYP2D6. Results: Four PMs were identified with the omeprazole phenotype probe and had a mean ± SD hydroxylation index of 1.335 ± 0.271. Nine EMs were selected based upon a hydroxylation index between 0.100 and 0.400 (mean 0.193 ± 0.079). FLV pharmacokinetic parameters (AUC, elimination half-life, Cmax and Tmax) did not significantly differ between the two groups. Genotype analysis for CYP2C19 revealed a mutant allele for the *2 which confirmed phenotype detection of PM status. Genotype analysis for CYP2D6*3 and *4 alleles showed that all PMs of CYP2C19 were EMs of CYP2D6. Conclusions: FLV disposition and dosing is unlikely to be affected by CYP2C19 polymorphism.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalDrug Metabolism and Drug Interactions
Volume19
Issue number1
StatePublished - 2002
Externally publishedYes

Fingerprint

Fluvoxamine
Pharmacokinetics
Genotype
Phenotype
Cytochrome P-450 CYP2D6
Omeprazole
Hydroxylation
Alleles
Pharmacy Schools
Cytochrome P-450 CYP2C19
Cytochrome P-450 Enzyme System
Area Under Curve
Half-Life
Healthy Volunteers
Research
Pharmaceutical Preparations

Keywords

  • CYP2C19
  • Fluvoxamine
  • Genotype
  • Pharmacokinetics
  • Phenotype

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Jann, M. W., ZumBrunnen, T. L., Kazmi, Y. R., VanDenBerg, C. M., Desai, H. D., Weidler, D. J., & Flockhart, D. A. (2002). Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabolism and Drug Interactions, 19(1), 1-11.

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. / Jann, Michael W.; ZumBrunnen, Troy L.; Kazmi, Yusuf R.; VanDenBerg, Chad M.; Desai, Hiral D.; Weidler, Donald J.; Flockhart, David A.

In: Drug Metabolism and Drug Interactions, Vol. 19, No. 1, 2002, p. 1-11.

Research output: Contribution to journalArticle

Jann, MW, ZumBrunnen, TL, Kazmi, YR, VanDenBerg, CM, Desai, HD, Weidler, DJ & Flockhart, DA 2002, 'Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype', Drug Metabolism and Drug Interactions, vol. 19, no. 1, pp. 1-11.
Jann MW, ZumBrunnen TL, Kazmi YR, VanDenBerg CM, Desai HD, Weidler DJ et al. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabolism and Drug Interactions. 2002;19(1):1-11.
Jann, Michael W. ; ZumBrunnen, Troy L. ; Kazmi, Yusuf R. ; VanDenBerg, Chad M. ; Desai, Hiral D. ; Weidler, Donald J. ; Flockhart, David A. / Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. In: Drug Metabolism and Drug Interactions. 2002 ; Vol. 19, No. 1. pp. 1-11.
@article{627f85dbd5c149cd8dca8457249cf12f,
title = "Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype",
abstract = "Objective: To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19. Methods: This was a prospective, open-label study conducted at the Clinical Research Unit School of Pharmacy. Fifty-seven healthy, nonsmoking volunteers aged 21-40 years participated. Subjects abstained from caffeinated products 12 hours prior to and during each testing period. To assess CYP2C19 activity, blood samples were collected from each subject prior to and two hours after a single dose of omeprazole 20 mg. Once PMs were identified, a sample population of EMs were selected for comparison between the two groups regarding FLV disposition. A single 100 mg FLV dose was given to EMs and PMs; blood samples for FLV analysis were obtained prior to drug administration and 0.5, 1, 2, 3, 4 6, 8, 12 and 24 hours later. A blood sample one day prior to FLV administration was also obtained for CYP2C19 and CYP2D6. Results: Four PMs were identified with the omeprazole phenotype probe and had a mean ± SD hydroxylation index of 1.335 ± 0.271. Nine EMs were selected based upon a hydroxylation index between 0.100 and 0.400 (mean 0.193 ± 0.079). FLV pharmacokinetic parameters (AUC, elimination half-life, Cmax and Tmax) did not significantly differ between the two groups. Genotype analysis for CYP2C19 revealed a mutant allele for the *2 which confirmed phenotype detection of PM status. Genotype analysis for CYP2D6*3 and *4 alleles showed that all PMs of CYP2C19 were EMs of CYP2D6. Conclusions: FLV disposition and dosing is unlikely to be affected by CYP2C19 polymorphism.",
keywords = "CYP2C19, Fluvoxamine, Genotype, Pharmacokinetics, Phenotype",
author = "Jann, {Michael W.} and ZumBrunnen, {Troy L.} and Kazmi, {Yusuf R.} and VanDenBerg, {Chad M.} and Desai, {Hiral D.} and Weidler, {Donald J.} and Flockhart, {David A.}",
year = "2002",
language = "English (US)",
volume = "19",
pages = "1--11",
journal = "Drug Metabolism and Personalized Therapy",
issn = "2363-8907",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

AU - Jann, Michael W.

AU - ZumBrunnen, Troy L.

AU - Kazmi, Yusuf R.

AU - VanDenBerg, Chad M.

AU - Desai, Hiral D.

AU - Weidler, Donald J.

AU - Flockhart, David A.

PY - 2002

Y1 - 2002

N2 - Objective: To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19. Methods: This was a prospective, open-label study conducted at the Clinical Research Unit School of Pharmacy. Fifty-seven healthy, nonsmoking volunteers aged 21-40 years participated. Subjects abstained from caffeinated products 12 hours prior to and during each testing period. To assess CYP2C19 activity, blood samples were collected from each subject prior to and two hours after a single dose of omeprazole 20 mg. Once PMs were identified, a sample population of EMs were selected for comparison between the two groups regarding FLV disposition. A single 100 mg FLV dose was given to EMs and PMs; blood samples for FLV analysis were obtained prior to drug administration and 0.5, 1, 2, 3, 4 6, 8, 12 and 24 hours later. A blood sample one day prior to FLV administration was also obtained for CYP2C19 and CYP2D6. Results: Four PMs were identified with the omeprazole phenotype probe and had a mean ± SD hydroxylation index of 1.335 ± 0.271. Nine EMs were selected based upon a hydroxylation index between 0.100 and 0.400 (mean 0.193 ± 0.079). FLV pharmacokinetic parameters (AUC, elimination half-life, Cmax and Tmax) did not significantly differ between the two groups. Genotype analysis for CYP2C19 revealed a mutant allele for the *2 which confirmed phenotype detection of PM status. Genotype analysis for CYP2D6*3 and *4 alleles showed that all PMs of CYP2C19 were EMs of CYP2D6. Conclusions: FLV disposition and dosing is unlikely to be affected by CYP2C19 polymorphism.

AB - Objective: To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19. Methods: This was a prospective, open-label study conducted at the Clinical Research Unit School of Pharmacy. Fifty-seven healthy, nonsmoking volunteers aged 21-40 years participated. Subjects abstained from caffeinated products 12 hours prior to and during each testing period. To assess CYP2C19 activity, blood samples were collected from each subject prior to and two hours after a single dose of omeprazole 20 mg. Once PMs were identified, a sample population of EMs were selected for comparison between the two groups regarding FLV disposition. A single 100 mg FLV dose was given to EMs and PMs; blood samples for FLV analysis were obtained prior to drug administration and 0.5, 1, 2, 3, 4 6, 8, 12 and 24 hours later. A blood sample one day prior to FLV administration was also obtained for CYP2C19 and CYP2D6. Results: Four PMs were identified with the omeprazole phenotype probe and had a mean ± SD hydroxylation index of 1.335 ± 0.271. Nine EMs were selected based upon a hydroxylation index between 0.100 and 0.400 (mean 0.193 ± 0.079). FLV pharmacokinetic parameters (AUC, elimination half-life, Cmax and Tmax) did not significantly differ between the two groups. Genotype analysis for CYP2C19 revealed a mutant allele for the *2 which confirmed phenotype detection of PM status. Genotype analysis for CYP2D6*3 and *4 alleles showed that all PMs of CYP2C19 were EMs of CYP2D6. Conclusions: FLV disposition and dosing is unlikely to be affected by CYP2C19 polymorphism.

KW - CYP2C19

KW - Fluvoxamine

KW - Genotype

KW - Pharmacokinetics

KW - Phenotype

UR - http://www.scopus.com/inward/record.url?scp=0036381764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036381764&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 1

EP - 11

JO - Drug Metabolism and Personalized Therapy

JF - Drug Metabolism and Personalized Therapy

SN - 2363-8907

IS - 1

ER -